Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/08820139.2021.1936009 http://scihub22266oqcxt.onion/10.1080/08820139.2021.1936009 34109900!8204310!34109900     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunol+Invest 2021 ; 50 (7): 802-809 Nephropedia Template TP {{tp|p=34109900|t=2021. SARS-CoV-2: Unique Challenges of the Virus and Vaccines |pdf=|usr=}}{{34109900}} gab.com Text SARS-CoV-2: Unique Challenges of the Virus and Vaccines JO: Immunol Invest http://www.kidney.de/pget.php?&tw=1&pmid=34109900 #FOAvip In November 2019, the highly infectious coronavirus SARS-CoV-2 emerged in Wuhan, China, and has since spread to almost all countries worldwide. Since its emergence, the COVID-19 infection has led to significant public health, economic and social problems. The current pandemic has inspired researchers to make every effort to design and develop an effective COVID-19 vaccine to provide sufficient protection against the virus and control the infection. In December 2020, the Pfizer vaccine was the first COVID-19 vaccine given Emergency Use Authorization (EUA), and the second FDA so-approved vaccine was the Moderna mRNA-1273 vaccine, which was introduced a week later. Both Pfizer and Moderna vaccines are mRNA-based vaccines, and are estimated to have an efficacy rate of more than 94%. The aim of this article is to provide a review of the attempts made to develop safe SARS-CoV-2 vaccines, highlighting potential challenges and concerns, such as disease enhancement, virus mutations, and public acceptance of the vaccine. Twit Text FOAVip SARS-CoV-2: Unique Challenges of the Virus and Vaccines ????Immunol Invest http://www.kidney.de/pget.php?&tw=1&pmid=34109900 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34109900 #FOAvip English Wikipedia <ref>{{Cite pmid|34109900}}</ref> SARS-CoV-2: Unique Challenges of the Virus and Vaccines #MMPMID34109900 Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND Immunol Invest 2021[Oct]; 50 (7): 802-809 PMID34109900show ga In November 2019, the highly infectious coronavirus SARS-CoV-2 emerged in Wuhan, China, and has since spread to almost all countries worldwide. Since its emergence, the COVID-19 infection has led to significant public health, economic and social problems. The current pandemic has inspired researchers to make every effort to design and develop an effective COVID-19 vaccine to provide sufficient protection against the virus and control the infection. In December 2020, the Pfizer vaccine was the first COVID-19 vaccine given Emergency Use Authorization (EUA), and the second FDA so-approved vaccine was the Moderna mRNA-1273 vaccine, which was introduced a week later. Both Pfizer and Moderna vaccines are mRNA-based vaccines, and are estimated to have an efficacy rate of more than 94%. The aim of this article is to provide a review of the attempts made to develop safe SARS-CoV-2 vaccines, highlighting potential challenges and concerns, such as disease enhancement, virus mutations, and public acceptance of the vaccine. |2019-nCoV Vaccine mRNA-1273[MESH] |Animals[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*immunology[MESH] |China[MESH] |Humans[MESH]SARS-CoV-2: Unique Challenges of the Virus and Vaccines (epmc).pdf DeepDyve Pubget Overpricing